Blood Banking/Virucidal

Hypericin Profile To Potentially Include Hepatitis C and HIV

Published in AIDS Weekly, April 24th, 1995

VIMRx Pharmaceuticals Inc., Stamford, Connecticut, announced that its program to develop hypericin, its lead antiviral/antiretroviral compound, to inactivate viruses in blood used for transfusions is yielding encouraging data which broaden the antiviral profile to potentially include hepatitis C as well as HIV.

Hepatitis C virus (HCV) infects about 200,000 people in the United States each year. Seventy-90 percent of these infections become chronic, thus 140,000 to 180,000 Americans become chronic carriers annually. These chronic infections carry a high risk of development of cirrhosis and liver cancer which appear later in life.

It is estimated by...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1995-04-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry